• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Epizyme earns $4M in milestones from GSK for novel HMT therapeutics

Epizyme earns $4M in milestones from GSK for novel HMT therapeutics

October 4, 2012
CenterWatch Staff

Epizyme, a pharmaceutical company focused personalized therapeutics for cancer, received a $4 million milestone payments from collaborator GlaxoSmithKline based on the achievement of pre-clinical milestones.

In 2011, Epizyme and GSK formed a worldwide strategic alliance to discover, develop and market novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases. This most recent milestone payment follows another $4 million in milestone payments from GSK to Epizyme in October 2011, bringing the total milestone payments to Epizyme to $8 million to date.

"Collaborations with companies such as GSK are an integral part of our strategy to build a new leading biopharm company that commercializes products in the United States," said Jason Rhodes, executive vice president and chief business officer. "Since January 2011, we have entered into benchmark alliances with GSK, Eisai and Celgene that together have brought in $140 million in cash, with future committed research funding and expected milestones. Importantly, Epizyme retains significant U.S. rights to our lead DOT1L and EZH2 programs, which are partnered with Celgene and Eisai, respectively, in addition to our pipeline of unpartnered programs."

The GSK alliance leverages Epizyme's product platform—including its proprietary biology, biochemistry, medicinal chemical and intellectual property—to discover and develop HMT therapeutics against the defined set of targets included in the collaboration. Epizyme received an upfront payment of $20 million and also receives committed research funding. Epizyme is eligible to receive more than $630 million in total milestone payments if medicines are commercialized for all targets in the collaboration. Additionally, Epizyme is eligible to receive up to double-digit royalties on worldwide net sales of collaboration products. For each collaboration target, Epizyme is primarily responsible for research up to development candidate selection, and GSK will be solely responsible for development and commercialization.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing